👋 New here? A quick tour of the page
📂
Sector tabs
Filter the analysis to a single sector, or stay on the first tab for the full market scan.
📈
Stock cards
Stocks ranked by positive mentions × average sentiment. Open "Why is it moving?" on any card to read the exact headlines behind the score — each one links to its original article.
🔍
Search a stock
Use the sidebar search to look up any tracked ticker or company name and see its bullish and bearish headlines side by side.
📡
Refresh & custom feeds
Hit Refresh Analysis to re-scan the latest news, or add your own RSS feed in the sidebar to include it in the scan.
Pharma picks
Ranked by positive mention count × average VADER sentiment score.
LLY
0.559
$1410.99
▼
0.46%
41 mentions
Why is LLY moving?
▲ Why it may be rising
- CNBC Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs They're the latest metrics on how much the new Me…
- trefis.com Could You Have Seen Merck Stock's Pipeline Run Coming? Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for th…
- Yahoo Finance Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?
▼ Why it may be falling
- fool.com Eli Lilly Stock Is On Track to Do Something It Hasn't Done Since 2016 The top healthcare stock has been underperforming the market, and its returns haven't been…
- MarketWatch This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month Viking Therapeutics is developing VK2735, a…
- Yahoo Finance Eli Lilly vs. Novo: The Obesity-Drug Battle Is Entering Its Next Round
PFE
0.412
$30.67
▲
0.49%
20 mentions
Why is PFE moving?
▲ Why it may be rising
- Nasdaq Is Pfizer an Excellent Dividend Stock to Buy? Pfizer (NYSE: PFE) has experienced unprecedented circumstances in the previous decade.
- Investing.com Pfizer to share overseas drug revenue with HHS under pricing deal
- Yahoo Finance Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?
▼ Why it may be falling
- trefis.com Was Moderna Stock's Cancer Vaccine Run Visible In Advance? Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 t…
- Nasdaq Pfizer's Tilrekimig Meets Phase 2 Primary Endpoint In Atopic Dermatitis (RTTNews) - Pfizer Inc. (PFE) reported Thursday that its ongoing Phase 2 study of invest…
- Nasdaq Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield Key PointsPfizer shares have underperformed since 2021, with the recent poor performance reflect…
JNJ
0.514
$270.56
▼
0.97%
19 mentions
Why is JNJ moving?
▲ Why it may be rising
- Nasdaq Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could Signal Key PointsJohnson & Johnson announ…
- trefis.com Could You Have Seen Merck Stock's Pipeline Run Coming? Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for th…
- Nasdaq AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? Key PointsAbbVie continues to diversify its portfolio into neuroscience and aesthe…
▼ Why it may be falling
- trefis.com Was The Run In JNJ Stock Hiding In Plain Sight? Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 h…
- Nasdaq J&J's Tremfya Shows Sustained Remission In Crohn's Disease Through 3 Years (RTTNews) - Johnson & Johnson (JNJ) reported three-year data showing sustained clinic…
- Yahoo Finance Health Bellwether J&J Slumps As Middle East Conflict Hampers Medtech Sales Johnson & Johnson stock fell early Tuesday as the conflict in the Middle East weighte…
MRNA
0.504
$220.83
▼
0.40%
17 mentions
Why is MRNA moving?
▲ Why it may be rising
- Fortune Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug CI is pairing top AI and bi…
- MarketWatch Citi tells investors it’s time to sell Moderna after 600%-plus stock gains Revenue and profit forecasts fail to justify the hype baked into Moderna’s share pric…
- investorshub.advfn.com Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility Shares of Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) declined on Wednesd…
▼ Why it may be falling
- trefis.com Was Moderna Stock's Cancer Vaccine Run Visible In Advance? Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 t…
- Yahoo Finance Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell. Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vacci…
- thestreet.com Citi delivers major verdict after Moderna’s remarkable 703% run Moderna’s rally has priced in unrealistic expectations for its cancer drug sales.
MRK
0.517
$148.36
▼
0.78%
13 mentions
Why is MRK moving?
▲ Why it may be rising
- Yahoo Finance Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
- trefis.com Could You Have Seen Merck Stock's Pipeline Run Coming? Merck (MRK) stock gained about 89% in the year from mid-September 2025, against a 17.1% price gain for th…
- Nasdaq Merck Signs $2.13 Bln License Deal With SciBrunch Therapeutics For KRAS G12D Inhibitor (RTTNews) - Merck & Co., Inc. (MRK), an American multinational pharmaceut…
▼ Why it may be falling
- trefis.com Was Moderna Stock's Cancer Vaccine Run Visible In Advance? Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 t…
- CNBC Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make His comments come after Merck officially opened its new 120,000-square-fo…
- CNBC Moderna shares plunge after cancer vaccine data leaks — despite positive results Moderna released full data on its closely watched cancer vaccine developed with…
AMGN
0.632
$465.45
▼
0.12%
11 mentions
Why is AMGN moving?
▲ Why it may be rising
- Yahoo Finance Amgen or Merck: Which Drugmaker Has the Stronger Dividend Growth Story?
- Nasdaq 2 Healthcare Stocks That Just Delivered Great News for Investors Key PointsVertex Pharmaceuticals and Amgen recently posted strong clinical trial results for pr…
- Nasdaq Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? Key PointsAmgen offers a diversified portfolio of established therapies across on…
▼ Why it may be falling
- Nasdaq How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? Key PointsAmgen, Pfizer, J&J, AbbVie, and Bristol Myers Squi…
- trefis.com Is Amgen Stock Increasing Your Market Risk? Investors holding shares of Amgen (AMGN), the $234 billion maker of drugs such as Repatha and Prolia, likely pair th…
- CNBC Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer A drug from Amgen could give patients with an aggressive form of lung ca…
BMY
0.483
$63.02
▲
0.86%
10 mentions
Why is BMY moving?
▲ Why it may be rising
- Nasdaq Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? Key PointsBristol Myers Squibb's Growth Portfolio sales rose 15% in the s…
- Nasdaq AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? Key PointsAbbVie continues to grow its revenue base by successfully transitioni…
- fool.com Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? Bristol Myers Squibb isn't a growth stock, but it may offer somethin…
▼ Why it may be falling
- Nasdaq 3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation Key PointsBristol Myers Squibb's stock price is up 42.5% in the past 12 months, yet it still…
- Nasdaq How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? Key PointsAmgen, Pfizer, J&J, AbbVie, and Bristol Myers Squi…
- Nasdaq Have $1,000 to Invest? This Dirt Cheap Pharma Stock Pays You 4.2% to Wait. Key PointsBristol Myers Squibb has a moderately high forward dividend yield, but that…
GILD
0.597
$170.33
▼
0.21%
8 mentions
Why is GILD moving?
▲ Why it may be rising
- Yahoo Finance Why Morgan Stanley likes Gilead's HIV prevention play
- Yahoo Finance Gilead Has Outperformed the S&P 500. But is its Valuation Still Attractive? Gilead Sciences, Inc. (NASDAQ:GILD) has had a considerably better year than the broa…
- MarketWatch Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer bets Shares of AbbVie, Eli Lilly and Gilead Sciences closed near recor…
ZTS
0.355
$83.18
▲
4.34%
7 mentions
Why is ZTS moving?
▲ Why it may be rising
- Nasdaq Zoetis (ZTS) Shares Cross 3% Yield Mark Looking at the universe of stocks we cover at Dividend Channel, in trading on Monday, shares of Zoetis Inc (Symbol: ZTS)…
- Yahoo Finance Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1…
- Yahoo Finance Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to…
AZN
0.617
$186.58
▼
0.04%
2 mentions
Why is AZN moving?
▲ Why it may be rising
- Nasdaq AstraZeneca: CHMP Recommends Enhertu For Approval In The EU (RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) and Daiichi Sankyo's (4568.T) Enhertu has been…
- Nasdaq AstraZeneca's Tezspire Shows Sustained Benefits In Phase 3 Esophagitis Trial (RTTNews) - AstraZeneca (AZN) said Tuesday that full results from the Phase 3 CROSS…
▼ Why it may be falling
- Yahoo Finance AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England
- Investing.com AstraZeneca, Daiichi Sankyo partner with Summit on cancer trial
- CNBC Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer A drug from Amgen could give patients with an aggressive form of lung ca…
BIIB
0.818
$249.01
▼
1.82%
1 mention
Why is BIIB moving?
▲ Why it may be rising
⚠ Legal Disclaimer
This tool is for educational purposes only. It does not constitute financial, investment, or legal advice. The sentiment scores and stock mentions shown here are derived from automated analysis of publicly available news and should not be used as the basis for any trading or investment decision. Past sentiment signals are not indicative of future stock performance. The creators of NewsToStocks accept no liability for any financial losses or decisions made based on this tool. Always consult a licensed financial advisor before making investment decisions.
📰 Data sources Stock prices via Yahoo Finance. News headlines from Reuters, Yahoo Finance, MarketWatch, CNBC, The Wall Street Journal, TechCrunch, Fortune, Business Insider, Investing.com, Nasdaq, CNN Business, and Reddit — each headline links to its original article, with the source publication tagged alongside it.
📰 Data sources Stock prices via Yahoo Finance. News headlines from Reuters, Yahoo Finance, MarketWatch, CNBC, The Wall Street Journal, TechCrunch, Fortune, Business Insider, Investing.com, Nasdaq, CNN Business, and Reddit — each headline links to its original article, with the source publication tagged alongside it.